Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“Randomized data already say treating the primary helps in oligometastatic prostate cancer: STAMPEDE showed prostate RT improved OS in low-volume disease (HR 0.68). This SEER simulation tests how far that reaches.
SEER target-trial emulation (2010-2022): 16,740 men with newly diagnosed metastatic disease, comparing early (≤6 mo) vs deferred vs no primary local therapy.
Early therapy: overall OS HR 0.96, about a 5-day survival gain at 36 months.
Benefit only in bone-only disease (HR 0.93)
Worse with lung-only (HR 1.45) or liver mets (HR 1.14), likely confounding by indication.
Are you treating the primary beyond low-volume, bone-only disease?”
Other articles about Katy Beckermann on OncoDaily.